

(20402, 204126)

(Content formerly found in: *Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome [BRCA1/BRCA2]*, *Genetic Testing for CHEK2 Mutations for Breast Cancer* and *Genetic Testing for PALB2 Mutations Protocols*)

Medical Benefit		Effective Date: 07/01/17	Next Review Date: 09/17
Preauthorization	Yes	Review Dates: 02/07, 01/08, 11/08, 09/09, 05/10, 05/11, 01/12, 01/13, 01/14, 05/14, 05/15, 05/16, 09/16, 03/17	

Preauthorization is required for services which may be medically necessary under this protocol. For tests that this protocol considers investigational, if the physician feels the service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

Populations	Interventions	Comparators	Outcomes
Individuals: <ul style="list-style-type: none"> With cancer, or a personal or family cancer history and criteria suggesting a risk of hereditary breast/ovarian cancer syndrome 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for a <i>BRCA1</i> or <i>BRCA2</i> mutation 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity Morbid events Quality of life Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> With risk of hereditary breast/ovarian cancer 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for a <i>PALB2</i> variant 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> With risk of hereditary breast/ovarian cancer 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for <i>CHEK2</i> variant 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease specific survival Test accuracy Test validity
Individuals: <ul style="list-style-type: none"> With risk of hereditary breast/ovarian cancer 	Interventions of interest are: <ul style="list-style-type: none"> Genetic testing for an <i>ATM</i> variant 	Comparators of interest are: <ul style="list-style-type: none"> No genetic testing 	Relevant outcomes include: <ul style="list-style-type: none"> Overall survival Disease-specific survival Test accuracy Test validity

Description

Hereditary breast and ovarian cancer (HBOC) syndrome describes the familial cancer syndromes that are related to mutations in the *BRCA* genes (*BRCA1* located on chromosome 17q21, *BRCA2* located on chromosome 13q12-13). Families with HBOC syndrome have an increased susceptibility to breast cancer occurring at a young age, bilateral breast cancer, male breast cancer, ovarian cancer at any age, cancer of the fallopian tube, and primary peritoneal cancer as well as other cancers, such as prostate cancer, pancreatic cancer, gastrointestinal cancers, melanoma, and laryngeal cancer.

About 3% to 5% of women presenting for assessment for hereditary breast/ovarian cancer risk have a variant in a gene that moderately increases the risk of cancer, rather than having one of the well described familial breast/ovarian cancer syndromes (e.g., *BRCA1*, *BRCA2*). *PALB2*, *CHEK2*, and *ATM* variants are considered to be of moderate penetrance and carriers have an approximately two to four fold increased risk of developing breast cancer compared with the general population. Risk estimates may be higher in patients with a family history of breast cancer or for a specific variant.

Summary of Evidence

For individuals who have cancer or a personal or family cancer history and meeting criteria suggesting a risk of hereditary breast and ovarian cancer (HBOC) syndrome who receive genetic testing for a *BRCA1* or *BRCA2* mutation, the evidence includes a TEC Assessment and studies of mutation prevalence and cancer risk. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, morbid events, quality of life, and treatment-related morbidity. The accuracy of mutation testing has been shown to be high. Studies of lifetime risk of cancer for carriers of a *BRCA* mutation have shown a risk as high as 85%. Knowledge of *BRCA* mutation status in individuals at risk of a *BRCA* mutation may impact health care decisions to reduce risk, including intensive surveillance, chemoprevention, and/or prophylactic intervention. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with risk of hereditary breast/ovarian cancer who receive genetic testing for a *PALB2* variant, the evidence include studies of analytic validity, variant prevalence, and multiple studies of breast cancer risk, including one meta-analysis. Relevant outcomes are overall survival, disease-specific survival, and test accuracy and validity. The reported evidence supporting analytic validity is not substantial, but given current next-generation sequencing techniques with variant confirmation by conventional methods, high analytic sensitivity such as reported by Judkins et al (2015) is expected in a laboratory certified by the Clinical Laboratory Improvement Amendments meeting standards for high-complexity molecular diagnostics. Evidence supporting clinical validity was obtained from nine studies reporting relative risks or odds ratios (two studies estimated penetrance). Study designs included family segregation, kin-cohort, family-based case-control, and population-based case-control. The number of pathogenic variants identified in studies varied from one (founder variants) to 48. Relative risks for breast cancer associated with a *PALB2* variant ranged from 2.3 to 13.4, with the two family-based studies reporting the lowest values. Evidence on preventive interventions in women with *PALB2* variants is indirect, relying on studies of high-risk women and *BRCA* carriers. Compared with other screening modalities, magnetic resonance imaging (MRI) has a higher sensitivity, but increased false positives when high-risk women are screened. Screening recommendations for high-risk asymptomatic women include beginning at an earlier age and addition of MRI to mammography. However, there is no direct evidence and limited observational data suggesting improved outcomes. There is limited observational evidence that chemoprevention can decrease the risk of invasive cancers in high-risk women; the U.S. Preventive Services Task Force (USPSTF) report and National Comprehensive Cancer Network (NCCN) support a chemoprevention option. In high-risk women, prophylactic mastectomy (bilateral or contralateral) reduces the risk of breast cancer and breast cancer mortality and decision analytic models project increased life-expectancy. Prophylactic mastectomy can be accompanied by a

significant risk of adverse effects and studies have found a minority of asymptomatic BRCA carriers choose to undergo a bilateral prophylactic mastectomy. Given the penetrance of PALB2 variants, the outcomes following bilateral and contralateral prophylactic mastectomy examined in women with a family history consistent with hereditary breast cancer (including BRCA1 and BRCA2 carriers) can be applied to women with PALB2 variants—with the benefit to risk balance affected by penetrance. In women at high risk of hereditary breast cancer who would consider preventive interventions, identifying a PALB2 variant provides a more precise estimated risk of developing breast cancer compared with family history alone and can offer women a more accurate understanding of tradeoffs involved for any intervention. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with risk of hereditary breast/ovarian cancer who receive genetic testing of for a CHEK2 variant or an ATM variant, the evidence includes studies of analytic validity, variant prevalence, and studies of breast cancer risk. Relevant outcomes are overall survival, disease-specific survival, and test accuracy and validity. The available studies on clinical validity have demonstrated that both CHEK2 and ATM2 variants are of moderate penetrants, with lower relative risks for breast cancer than PALB2, and confer a risk of breast cancer two to four times that of the general population. Direct evidence for the clinical utility of genetic testing for CHEK2 or ATM variants in individuals with risk of hereditary breast/ovarian cancer was not identified. For women with high-risk hereditary cancer syndromes, interventions to decrease breast cancer risk in high-risk women include screening (e.g., starting at an early age, addition of MRI to mammography, and annually), chemoprevention, prophylactic mastectomy, and prophylactic oophorectomy. Following the logic applied in the case of PALB2, there is limited evidence that chemoprevention can decrease the risk of invasive cancers in high-risk women; the USPSTF report and NCCN support a chemoprevention option. In contrast to the case of PALB2, where the penetrance approaches that of a BRCA variant, there is unlikely to be a similar benefit-to-risk calculus for women with a CHEK2 variant making a decision about a prophylactic mastectomy. It is unclear that the relative risk associated with the moderate penetrance variants would increase risk enough beyond that already conferred by familial risk to change screening behavior. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy

For individuals from a family with a known deleterious BRCA1 or BRCA2 mutation, genetic testing for a BRCA1 or BRCA2 mutation may be considered **medically necessary**.

Genetic testing for a *BRCA1* and *BRCA2* mutation may be considered **medically necessary** for testing an individual with cancer or history of cancer AND for testing an unaffected individual with a strong family history of cancer when ANY of the following criteria are met:

- Diagnosed with breast cancer prior to 45 years of age; OR
- Diagnosed with two breast cancers prior to 50 years of age; OR
- Diagnosed at any age and at least one first-, second- or third-degree relative with breast cancer diagnosed at 50 years of age or younger; OR
- Multiple primary breast cancers or bilateral breast cancer; OR
- Male with breast cancer; OR
- Triple negative breast cancer diagnosed at 60 years of age or younger;
- Breast cancer and at least one first-, second- or third-degree male relative with breast cancer; OR

- Breast cancer AND two or more 1st-, 2nd-, or 3rd-degree relatives on the same side of the family with breast, ovarian, fallopian tube, primary peritoneal or pancreatic cancer; OR
- Ovarian, fallopian tube or primary peritoneal CA; OR
- Pancreatic cancer and two or more 1st-, 2nd-, or 3rd-degree relatives on the same side of the family with breast, ovarian, fallopian tube, primary peritoneal or pancreatic cancer; OR
- Ashkenazi Jewish descent and has a history of pancreatic cancer and a first-, second-, or third-degree relative on the same side of the family with breast, ovarian, fallopian tube, primary peritoneal or pancreatic cancer; OR
- The member has a history of breast cancer and belongs to a population at risk for specific mutations due to ethnic background (e.g., Ashkenazi Jewish, Icelandic, Swedish, Hungarian or Dutch descent).
- Family history of three or more first-, second- or third-degree relatives with breast (at least one of which has breast cancer prior to age 50), ovarian, fallopian tube or primary peritoneal cancer.
- Large genomic rearrangement testing (BART) when testing for mutations is negative in individuals who meet criteria for genetic testing.
- Personal history of epithelial ovarian cancer

Unless criteria above are met, genetic testing either for those affected by breast, ovarian, fallopian tube, or primary peritoneal cancer or for unaffected individuals, including those with a family history of pancreatic cancer, is considered **investigational**.

Genetic testing in minors for BRCA1 and BRCA2 mutations is **investigational**.

BRCA and BART testing as a screening test for cancer in women in the general population is **investigational**.

Testing for *CHEK2* and *ATM* genetic abnormalities (mutations, deletions, etc.) is **investigational**.

Testing for PALB2 is **investigational**.

BRCA and BART testing for unaffected members of high-risk populations (e.g., Ashkenazi Jewish descendant) who have no relatives with a history of breast, ovarian, fallopian tube or primary peritoneal cancer at any age is **investigational**.

Genetic testing using multi-gene panels is **investigational**.

NGS (Next Generation Sequencing), when used for genetic testing for BRCA1, BRCA2, PALB2 and CHEK2 mutations, is **investigational**.

Policy Guidelines

This testing is necessary only once per lifetime.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter

the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

Hereditary breast and ovarian cancer

Current U.S. Preventive Services Task Force (USPSTF) guidelines recommend screening women with any family history of breast, ovarian, tubal, or peritoneal cancer. Women with positive screening results should receive genetic counseling and, if indicated after counseling, *BRCA* testing. (Grade B Recommendation)

Recommended screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in *BRCA1* or *BRCA2* are:

- Ontario Family History Assessment Tool (FHAT)
- Manchester Scoring System
- Referral Screening Tool (RST)
- Pedigree Assessment Tool (PAT)
- Family History Screen (FHS-7)

A Recommended Testing Strategy

- In patients with known familial *BRCA* mutation:
 - Targeted testing for the specific, known mutation only.
- In patients with unknown familial *BRCA* mutation:
 - If more than one family member is affected with cancers highly associated with a particular inherited cancer susceptibility syndrome, consider testing first a family member most likely to carry a mutation, such as the youngest age at diagnosis, bilateral disease, multiple primary cancers, or other cancers associated with the syndrome, or most closely related to the proband/patient.
 - If no living family member with breast or ovarian cancer exists, NCCN suggests testing first- or second-degree family members affected with a different cancer type that is thought to be related to deleterious *BRCA1* or *BRCA2* mutations (e.g., prostate cancer, pancreatic cancer, and melanoma).
- If no familial mutation can be identified, two possible testing strategies are:
 - Full sequencing followed by testing for common large genomic rearrangements (deletions/duplications), only if sequencing detects no mutation (negative result).
 - Alternatively, simultaneous full sequencing and testing for common large genomic rearrangements (also known as comprehensive *BRCA* testing; see Comprehensive Mutation Analysis, below) may be performed as is recommended by NCCN.
 - If following full sequencing and testing for common large genomic rearrangements is negative, testing for uncommon large genomic rearrangements (e.g., Myriad's BART) may be done.
- If of Ashkenazi Jewish descent:
 - In Ashkenazi Jewish patients, testing for founder-specific mutation(s) should be performed first. Comprehensive genetic testing may be considered if ancestry also includes non-Ashkenazi Jewish relatives or if other HBOC criteria are met.
 - In members of known Ashkenazi Jewish descent, NCCN recommends testing for the three known founder mutations (185delAG and 5182insC in *BRCA1*; 6174delT in *BRCA2*) first.

- If testing is negative for founder mutations, comprehensive genetic testing may be considered (see Comprehensive Mutation Analysis, below).

Comprehensive Mutation Analysis

Comprehensive mutation analysis currently includes sequencing the coding regions and intron and exon splice sites, as well as testing to detect common large deletions and rearrangements that can be missed with sequence analysis alone. In addition, before August 2006, testing for large deletions and rearrangements was not performed, thus some patients with familial breast cancer who had negative *BRCA* testing before this time may consider repeat testing for the rearrangements.

High-Risk Ethnic Groups

Testing in eligible individuals who belong to ethnic populations in which there are well-characterized founder mutations should begin with tests specifically for these mutations. For example, founder mutations account for approximately three quarters of the *BRCA* mutations found in Ashkenazi Jewish populations. When testing for founder mutations is negative, comprehensive mutation analysis should then be performed.

Testing Unaffected Individuals

In unaffected family members of potential *BRCA* mutation families, most test results will be negative and uninformative. Therefore, it is strongly recommended that an affected family member be tested first whenever possible to adequately interpret the test. Should a *BRCA* mutation be found in an affected family member(s), DNA from an unaffected family member can be tested specifically for the same mutation of the affected family member without having to sequence the entire gene. Interpreting test results for an unaffected family member without knowing the genetic status of the family may be possible in the case of a positive result for an established disease-associated mutation but leads to difficulties in interpreting negative test results (uninformative negative) or mutations of uncertain significance because the possibility of a causative *BRCA* mutation is not ruled out.

Prostate Cancer

Patients with *BRCA* mutations have an increased risk of prostate cancer, and patients with known *BRCA* mutations may therefore consider more aggressive screening approaches for prostate cancer. However, the presence of prostate cancer in an individual, or in a family, is not itself felt to be sufficient justification for *BRCA* testing.

Background

Breast Cancer and Genetics

In 2016, researchers anticipate breast cancer will be diagnosed in 246,660 women and 40,450 will die from the disease¹; a woman's lifetime risk is 12.3% (seer.cancer.gov/statfacts/html/breast.html). Breast cancers can be classified as sporadic, familial, or hereditary.² Most are sporadic (70% to 75%), occurring in women without a family history of disease. Familial cancers (15% to 25%) aggregate within families but lack clearly discernable patterns of inheritance and are likely polygenic. Hereditary cancers have discernable inheritance patterns, often occur at younger ages, may be bilateral, and comprise between 5% and 10% of breast cancers. Pathogenic *BRCA1* and *BRCA2* variants appear responsible for 20% to 25% of hereditary breast cancers, a while small proportions are attributed to pathogenic variants in other highly penetrant genes (e.g., *TP53*, *CDH1*, *PTEN*, *STK11*).

Hereditary breast and ovarian cancer

Several genetic syndromes with an autosomal dominant pattern of inheritance that feature breast cancer have

been identified. Of these, HBOC and some cases of hereditary site-specific breast cancer have in common causative mutations in *BRCA* (breast cancer susceptibility) genes. Families suspected of having HBOC syndrome are characterized by an increased susceptibility to breast cancer occurring at a young age, bilateral breast cancer, male breast cancer, ovarian cancer at any age, as well as cancer of the fallopian tube and primary peritoneal cancer. Other cancers, such as prostate cancer, pancreatic cancer, gastrointestinal cancers, melanoma, and laryngeal cancer, occur more frequently in HBOC families. Hereditary site-specific breast cancer families are characterized by early onset breast cancer with or without male cases, but without ovarian cancer. For this protocol, we refer collectively to both as hereditary breast and/or ovarian cancer.

Germline mutations in the *BRCA1* and *BRCA2* genes are responsible for the cancer susceptibility in most HBOC families, especially if ovarian cancer or male breast cancer are features. However, in site-specific breast cancer, *BRCA* mutations are responsible only for a proportion of affected families. *BRCA* gene mutations are inherited in an autosomal dominant fashion through either the maternal or paternal lineage. It is possible to test for abnormalities in *BRCA1* and *BRCA2* genes to identify the specific mutation in cancer cases and to identify family members with increased cancer risk. Family members without existing cancer who are found to have *BRCA* mutations can consider preventive interventions for reducing risk and mortality.

Penetrance of Pathogenic Variants

Penetrance is the risk conferred by a pathogenic variant, or the proportion of individuals with the variant expected to develop cancer. Variant penetrance is considered high, moderate, or low according to lifetime risk: high (> 50%), moderate (20% to 50%), and low (< 20%) (corresponding relative risks of approximately ≥ 5 , 1.5 to 5, and < 1.53). Variants in only a few breast cancer-susceptibility genes (*BRCA1* and *BRCA2* [hereditary breast/ovarian cancer syndrome], *TP53* [Li-Fraumeni syndrome], *PTEN* [Cowden syndrome], *CDH1* [hereditary diffuse gastric cancer], *STK11* [Peutz-Jeghers syndrome]) are considered highly penetrant. For example, a woman with a *BRCA1* or *BRCA2* variant has roughly a 75% lifetime risk of developing breast cancer and a relative risk of 11 to 12 compared with the general population.⁴

Penetrance can be modified by environmental factors and by family history, which is a particularly important modifier for low- and moderate-penetrance genes. In addition, specific pathogenic variants within a gene may confer somewhat different risks.

In contrast, about 3% to 5% of women presenting for hereditary breast/ovarian cancer risk assessment have sequence variants in a moderate penetrance gene.

Determining Variant Pathogenicity

Determining the pathogenicity of variants in a cancer-susceptibility gene most commonly detected (e.g., founder sequence variants) is generally straightforward because associations are repeatedly observed. For uncommonly identified variants, such as those found in a few individuals or families, defining pathogenicity can be more difficult. For example, predicting the pathogenicity of previously unidentified variants typically requires *in silico* (computational) analysis predicting protein structure/function, evolutionary conservation, and splice site prediction.⁵ The approach to defining pathogenicity is clearly outlined in standards and reporting guidelines.⁵ Still, distinctions between a variant of uncertain significance and a pathogenic one from different laboratories may not always be identical.⁶

Genes Associated With a Moderate Penetrance of Breast Cancer

PALB2

The *PALB2* gene (partner and localizer of *BRCA2*) encodes for a protein first described in 2006.⁷ The gene is located at 16p12.2⁹ and has 13 exons (www.omim.org/entry/610355). The *PALB2* protein assists *BRCA2* in DNA repair and tumor suppression. Heterozygous pathogenic *PALB2* variants increase the risk of developing breast

and pancreatic cancers; homozygous variants are found in Fanconi anemia^b. PALB2 variants are truncating frameshift or stop codons, and are found throughout the gene. Pathogenic PALB2 variants are uncommon in unselected populations and prevalence varies by ethnicity and family history. For example, Antoniou et al (2014) assumed a prevalence of eight per 10,000 in the general population when modeling breast cancer risks.⁸ Variants are more prevalent in ethnic populations where founder variants have persisted (e.g., Finns, French Canadians, Poles), while infrequently found in others (e.g., in Ashkenazi Jews^{9,10}). In women with a family history of breast cancer, the prevalence of pathogenic PALB2 variants ranges between 0.9% and 3.9%,⁸ or substantially higher than in an unselected general population. Depending on population prevalence, PALB2 may be responsible for as much as 2.4% of hereditary breast cancers⁸; and in populations with founder variants cause 0.5% to 1% of all breast cancers.¹¹

Protein-truncating PALB2 variants appear responsible for some cases of familial pancreatic cancers, but the proportion is unclear. Whether screening asymptomatic high-risk patients for pancreatic cancer can improve health outcomes is uncertain.

CHEK2 Gene

The CHEK2 (checkpoint kinase 2) gene is activated in response to DNA double-strand breakage and plays a role in cell-cycle control, DNA repair, and apoptosis.

In 2002, a single recurrent truncating mutation in the CHEK2 gene (c.1100delC) was first reported as a cause of breast cancer, and studies have since confirmed this. The incidence of CHEK2 variants varies widely among populations. It is most prevalent in Eastern and Northern Europe, where the population frequency of the c.1100delC allele ranges from 0.5% to 1.4%; the allele is less frequent in North America and virtually absent in Spain and India.

Although most data for truncating CHEK2 variants are limited to the c.1100delC variant, three other founder variants of CHEK2 (IVS2+1G>A, del5395, I157T) have been associated with breast cancer in Eastern Europe. IVS2+1G>A and del5395 are protein-truncating variants, and I157T is a missense variant. The truncating variants are associated with breast cancer in the Slavic populations of Poland, Belarus, Russia, and the Czech Republic. The I157T variant has a wider geographic distribution, and has been reported to be associated with breast cancer in Poland, Finland, Germany, and Belarus.¹²

ATM Gene

ATM (ataxia-telangiectasia [AT] mutated), located on chromosome 11q22.3, is associated with the autosomal recessive condition AT. This condition is characterized by progressive cerebellar ataxia with onset between the ages of one and four years, telangiectasias of the conjunctivae, oculomotor apraxia, immune defects, and cancer predisposition. Female ATM heterozygotes carriers have a risk of breast cancer about twice as high as that of the general population, but do not appear to have an elevated ovarian cancer risk.

Identifying Women at Risk of an Inherited Susceptibility to Breast Cancer

Breast cancer risk can be affected by genetic and nongenetic factors. Risk is increased in women experiencing an earlier age at menarche, nulliparity, late age of first pregnancy, fewer births, late menopause, proliferative breast disease, menopausal hormone therapy, alcohol, obesity, inactivity, and radiation.¹³ A family history of breast cancer confers between a two and a four fold increased risk varying according to the number and closeness of affected relatives, age at which cancers developed, whether breast cancers were bilateral, and if other cancers occurred (e.g., ovarian).¹⁴ For a woman without breast cancer, the probability of detecting a pathogenic variant can be estimated from a detailed multigenerational pedigree (e.g., Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm),¹⁵ screening tools (e.g., BRCAPRO,¹⁶ Ontario Family History Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree Assessment Tool, Family History Screen^{17,18}), or by referring to guidelines that define specific family history criteria (see Table 1). For women with

breast cancer, family history also affects the likelihood of carrying a pathogenic variant, although somewhat different criteria are applied (see Table 2) as is risk assessment from a pedigree.¹⁵

Table 1. NCCN Criteria for Genetic Risk Evaluation of an Individual Without a History of Breast Cancer²

Individual Without a History of Breast Cancer
“A close relative with any of the following:
A known mutation in a cancer susceptibility gene within the family
≥ 2 breast cancer primaries in a single individual
≥ 2 individuals with breast cancer primaries on the same side of family with at least one diagnosed ≤ 50 years
Ovarian cancer
Male breast cancer
First- or second-degree relative with breast cancer ≤ 45 years
Family history of three or more of the following (especially if early onset and can include multiple primary cancers in same individual): breast, pancreatic cancer, prostate cancer (Gleason score ≥ 7), melanoma, sarcoma, adrenocortical carcinoma, brain tumors, leukemia, diffuse gastric cancer, colon cancer, endometrial cancer, thyroid cancer, kidney cancer, dermatologic manifestations, and/or macrocephaly, hamartomatous polyps of GI tract”

GI: gastrointestinal; NCCN: National Comprehensive Cancer Network.

Table 2. NCCN Criteria for Genetic Risk Evaluation of an Individual With Breast Cancer²

Individual With Breast Cancer
“A known sequence variant in a cancer susceptibility gene within the family:
Early-age-onset breast cancer
Triple negative (ER-, PR-, HER2-) breast cancer diagnosed ≤ 60 years
Two breast cancer primaries in a single individual
Breast cancer at any age, and
≥ 1 close blood relative with breast cancer ≤ 50 years, or
≥ 1 close blood relative with invasive ovarian cancer at any age, or
≥ 2 close blood relatives with breast cancer and/or pancreatic cancer at any age, or
From a population at increased risk
Male breast cancer
An individual of Ashkenazi Jewish descent with breast, ovarian, or pancreatic cancer at any age
An individual with a personal and/or family history of three or more of the following (especially if early onset and can include multiple primary cancers in same individual): breast, pancreatic cancer, prostate cancer (Gleason score ≥ 7), melanoma, sarcoma, adrenocortical carcinoma, brain tumors, leukemia, diffuse gastric cancer, colon cancer, endometrial cancer, thyroid cancer, kidney cancer, dermatologic manifestations, and/or macrocephaly, hamartomatous polyps of gastrointestinal (GI) tract.”
An individual with an ovarian cancer

ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; NCCN: National Comprehensive Cancer Network; PR: progesterone receptor.

Patient Populations

Genetic testing can be considered for women at increased risk of developing hereditary breast cancer based on their family history, or in women with breast cancer whose family history or cancer characteristics (e.g., triple-negative disease, young age) increase the likelihood that the breast cancer is hereditary. Testing may also be considered for women from families with known variants. Potential benefit derives from interventions (screening, chemoprevention, risk reducing surgery) that can prevent a first breast cancer, a contralateral breast cancer, or cancer in a different organ caused by the same variant. Whether benefit outweighs harms depends on the risk of developing breast cancer (a first cancer or a contralateral one), the effectiveness and the harms of interventions. Assessing the net health outcome requires:

1. that a test accurately identifies variants and pathogenicity can be determined;
2. that a variant alters (increasing or decreasing) a woman’s risk of developing breast cancer (including contralateral disease in women already diagnosed) sufficient to change decision making, and of a magnitude that

3. management changes informed by testing can lead to improved health outcomes.

Additionally, if a familial pathogenic variant is identified, asymptomatic at-risk family members may benefit from cascade testing for the known variant. If that variant is identified in an at-risk relative, then risk-reducing management options could be offered; if the familial variant is not identified, then the relative may be considered near population risk and could avoid increased surveillance for breast cancer and risk reducing options would not be considered.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA). Per the www.genetests.org website there are currently six CLIA-certified U.S. laboratories that offer sequence analysis of the entire gene coding and four that offer deletion, duplication, and copy number analysis. PALB2, CHEK2, and ATM testing are available under the auspices of CLIA (a list of laboratories offering testing is available at NCBI's Genetic Testing Registry <https://www.ncbi.nlm.nih.gov/gtr/>). To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this testing. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

Myriad Genetic Laboratories (Salt Lake City, UT) offers: (1) Comprehensive BRACAnalysis[®] that includes complete sequencing of *BRCA1* and *BRCA2* and gap polymerase chain reaction for five common rearrangements (deletions/duplications) in *BRCA1*; (2) BRACAnalysis[®] Large Rearrangement Test (BART[™]), which may be ordered as a reflex test for patients who test negative for Comprehensive BRACAnalysis[®] to detect uncommon large rearrangements in *BRCA1* and *BRCA2*; and (3) Integrated BRACAnalysis[®], which includes BART as part of *BRCA1* or *BRCA2* analysis.

Quest Diagnostics (Madison, NJ) offers BRCAVantage[™] that includes sequencing of *BRCA1* and *BRCA2* and a multiplex ligation-dependent probe amplification assay to detect both common and uncommon gene rearrangements.

LabCorp (Burlington, NC) offers the BRCAssureSM suite of tests which includes: targeted *BRCA1* and *BRCA2* analysis; a founder mutation panel for Ashkenazi Jewish patients (three mutations); comprehensive *BRCA1* and *BRCA2* analysis (full gene sequencing plus analysis of common and uncommon large rearrangements); and deletion/duplication analysis of uncommon large rearrangements only (without sequencing) when comprehensive analysis is negative.

Customized next-generation sequencing panels provide simultaneous analysis of multiple cancer predisposition genes, and typically include both intermediate- and high-penetrant genes.

Related Protocol

Genetic Cancer Susceptibility Panels Using Next-Generation Sequencing

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin.* Jan-Feb 2016; 66(1):7-30. PMID 26742998
2. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1.2017. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed December 1, 2016.
3. Nelson HD, Fu R, Goddard K et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 101. AHRQ Publication No. 12-05164-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
4. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med.* Jun 4 2015; 372(23):2243-2257. PMID 26014596
5. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* May 2015; 17(5):405-424. PMID 25741868
6. Kurian AW, Antoniou AC, Domchek SM. Refining breast cancer risk stratification: additional genes, additional information. *Am Soc Clin Oncol Educ Book.* 2016; 35:44-56. PMID 27249685
7. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. *Proc Natl Acad Sci U S A.* Sep 30 2014; 111(39):14205-14210. PMID 25192939
8. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. *JAMA: the journal of the American Medical Association.* Sep 17 2014; 312(11):1091-1092. PMID 25198398
9. Stein R. Researcher urges wider genetic screening for breast cancer. National Public Radio Shots: health news from NPR, 09/08/2014. http://www.npr.org/blogs/health/2014/09/08/346770167/researcher-urges-wider-genetic-screening-for-breast-cancer?utm_source=npr_email_a_friend&utm_medium=email&utm_content=20140909&utm_campaign=toryshare&utm_term. Accessed October 13, 2014.
10. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. *Journal of the National Cancer Institute.* Aug 21 2002; 94(16):1221-1226. PMID 12189225
11. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. *American journal of human genetics.* Apr 2000; 66(4):1259-1272. PMID 10739756
12. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol.* Oct 1 2011; 29(28):3747-3752. PMID 21876083
13. Schottenfeld D, Fraumeni JF. *Cancer epidemiology and prevention.* 3rd ed. New York: Oxford University Press; 2006.
14. Singletary SE. Rating the risk factors for breast cancer. *Ann Surg.* Apr 2003; 237(4):474-482. PMID 12677142
15. Antoniou AC, Pharoah PP, Smith P, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. *Br J Cancer.* Oct 18 2004; 91(8):1580-1590. PMID 15381934

16. Berry DA, Iversen ES, Jr., Gudbjartsson DF, et al. BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. *J Clin Oncol*. Jun 1 2002; 20(11):2701-2712. PMID 12039933
17. Nelson HD, Pappas M, Zakher B, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. *Annals of internal medicine*. Feb 18 2014; 160(4):255-266. PMID 24366442
18. Satagopan JM, Offit K, Foulkes W, et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. May 2001; 10(5):467-473. PMID 11352856
19. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. *Lancet*. Oct 24 1998; 352(9137):1337-1339. PMID 9802270
20. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. *Journal of the National Cancer Institute*. Jul 21 1999; 91(14):1241-1247. PMID 10413426
21. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science*. Oct 24 2003; 302(5645):643-646. PMID 14576434
22. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Jun 15 2004; 22(12):2328-2335. PMID 15197194
23. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *Journal of the National Cancer Institute*. Jun 5 2013; 105(11):812-822. PMID 23628597
24. Grann VR, Whang W, Jacobson JS, et al. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Feb 1999; 17(2):494-500. PMID 10080590
25. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *The New England journal of medicine*. Jan 14 1999; 340(2):77-84. PMID 9887158
26. Moller P, Borg A, Evans DG, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. *International journal of cancer. Journal international du cancer*. Oct 20 2002; 101(6):555-559. PMID 12237897
27. Olopade OI, Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. *The breast journal*. Jan-Feb 2004; 10 Suppl 1:S5-9. PMID 14984481
28. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *The New England journal of medicine*. May 23, 2002; 346(21):1616-1622. PMID 12023993
29. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Mar 1 2002; 20(5):1260-1268. PMID 11870168
30. Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. *Archives of surgery*. Dec 2003; 138(12):1323-1328; discussion 1329. PMID 14662532
31. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. *Cancer research*. Aug 15 2006; 66(16):8297-8308. PMID 16912212
32. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Mar 15 2002; 20(6):1480-1490. PMID 11896095

33. Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. *The New England journal of medicine*. Jan 18 1996; 334(3):137-142. PMID 8531967
34. Malone KE, Daling JR, Thompson JD, et al. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. *JAMA: the journal of the American Medical Association*. Mar 25 1998; 279(12):922-929. PMID 9544766
35. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. *The Breast Cancer Linkage Consortium. American journal of human genetics*. Mar 1998; 62(3):676-689. PMID 9497246
36. Hartge P, Struewing JP, Wacholder S, et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. *American journal of human genetics*. Apr 1999; 64(4):963-970. PMID 10090881
37. Hodgson SV, Heap E, Cameron J, et al. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. *Journal of medical genetics*. May 1999; 36(5):369-373. PMID 10353781
38. de Ruijter TC VJ, de Hoon JPJ, et al. Characteristics of triple-negative breast cancer. *Journal of cancer research and clinical oncology*. 2011; 137:183-192. PMID
39. Kandel MJ SD, Masciari S et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). *J Clin Onc*. 2006; 24(18S):508. PMID
40. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. *BMC cancer*. 2009; 9:86. PMID 19298662
41. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. Mar 1 2011; 17(5):1082-1089. PMID 21233401
42. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Feb 2007; 16(2):342-346. PMID 17301269
43. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Jan 20 2009; 27(3):433-438. PMID 19064968
44. Trainer AH, Meiser B, Watts K, et al. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. *International journal of gynecological cancer: official journal of the International Gynecological Cancer Society*. Jul 2010; 20(5):704-716. PMID 20973257
45. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. *Gynecologic oncology*. May 1, 2011; 121(2):353-357. PMID 21324516
46. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian (discussion update in progress), version 2.2015. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#genetics_screening. Accessed November 3, 2015.
47. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. *Gynecologic oncology*. May 2013; 129(2):364-371. PMID 23391663
48. Robson M, Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. *The New England journal of medicine*. Jul 12 2007; 357(2):154-162. PMID 17625127
49. Phillips KA, Jenkins MA, Lindeman GJ, et al. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. *Clinical genetics*. Sep 2006; 70(3):198-206. PMID 16922722

50. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. *The New England journal of medicine*. Jul 12 2007; 357(2):115-123. PMID 17625123
51. Lesnock JL, Darcy KM, Tian C, et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. *British journal of cancer*. Apr 2 2013; 108(6):1231-1237. PMID 23462720
52. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research*. Apr 1 2010; 16(7):2115-2121. PMID 20215531
53. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. May 10, 2013; 31(14):1748-1757. PMID 23569316
54. Mitra AV, Bancroft EK, Barbachano Y, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU Int*. Jan 2011; 107(1):28-39. PMID 20840664
55. Antoniou AC, Beesley J, McGuffog L, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer research*. Dec 1 2010; 70(23):9742-9754. PMID 21118973
56. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. *Cancer research*. Mar 15 2011; 71(6):2222-2229. PMID 21285249
57. Cox DG, Simard J, Sinnett D, et al. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human molecular genetics*. Sep 16 2011. PMID 21890493
58. Engel C, Versmold B, Wappenschmidt B, et al. Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Nov 2010; 19(11):2859-2868. PMID 20978178
59. Kleibl Z, Havranek O, Kormunda S, et al. The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development. *Journal of cancer research and clinical oncology*. Feb 2011; 137(2):331-338. PMID 20422428
60. Osorio A, Milne RL, Alonso R, et al. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. *British journal of cancer*. Apr 12 2011; 104(8):1356-1361. PMID 21427728
61. Ramus SJ, Kartsonaki C, Gayther SA, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*. Jan 19 2011; 103(2):105-116. PMID 21169536
62. Bianco A, Quaresima B, Pileggi C, et al. Polymorphic repeat length in the AIB1 gene and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis of observational studies. *PLoS One*. 2013; 8(3):e57781. PMID 23483928
63. Zhou GW, Hu J, Peng XD, et al. RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis. *Breast cancer research and treatment*. Jan 2011; 125(2):529-535. PMID 20623332
64. Metcalfe K, Lubinski J, Lynch HT, et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. *Journal of the National Cancer Institute*. Dec 15 2010; 102(24):1874-1878. PMID 21098759
65. Lancaster JM, Powell CB, Chen LM, et al. Statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecologic oncology*. Sep 17 2014. PMID 25238946

66. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. *JAMA: the journal of the American Medical Association*. Mar 22 2006; 295(12):1379-1388. PMID 16551709
67. Palma MD, Domchek SM, Stopfer J, et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. *Cancer research*. Sep 1 2008; 68(17):7006-7014. PMID 18703817
68. Armstrong J, Toscano M, Kotchko N, et al. American BRCA Outcomes and Utilization of Testing (ABOUT) Study: A Pragmatic Research Model that Incorporates Personalized Medicine/Patient-Centered Outcomes in a Real World Setting. *J Genet Couns*. Sep 12 2014. PMID 25209347
69. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *Journal of Clinical Oncology*. February 10, 2010; 28(5):893-901. PMID 20065170
70. Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines. The American College of Medical Genetics, Practice Guideline: 1999; <https://www.acmg.net/>. Accessed September 16, 2014.
71. Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. Feb 18 2014; 160(4):271-281. PMID 24366376
72. Palmetto GBA[®]. MolDX[®] approved gene testing (M00041), last updated 09/17/2014. <http://www.palmettogba.com/palmetto/MolDX.nsf/DocsCat/MolDx%20Website~MolDx~Browse%20By%20Topic~Covered%20Tests~9BMLRK6738?open&navmenu=Browse%5eBy%5eTopic|||>. Accessed October 15, 2014.
73. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. *Biomed Res Int*. 2013; 2013:747318. PMID 23586058
74. Shannon KM, Chittenden A. Genetic testing by cancer site: breast. *Cancer J*. Jul-Aug 2012; 18(4):310-319. PMID 22846731
75. Zhang YX, Wang XM, Kang S, et al. Common variants in the PALB2 gene confer susceptibility to breast cancer: a meta-analysis. *Asian Pac J Cancer Prev*. 2013; 14(12):7149-7154. PMID 24460267
76. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. *BMC Cancer*. 2015; 15(1):215. PMID 25886519
77. Fernandes PH, Saam J, Peterson J, et al. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer. *Cancer*. Apr 1 2014; 120(7):963-967. PMID 24415441
78. Ding YC, Steele L, Kuan CJ, et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. *Breast Cancer Res Treat*. Apr 2011; 126(3):771-778. PMID 20927582
79. Stadler ZK, Salo-Mullen E, Sabbaghian N, et al. Germline PALB2 mutation analysis in breast-pancreas cancer families. *J Med Genet*. Aug 2011; 48(8):523-525. PMID 21415078
80. Hofstatter EW, Domchek SM, Miron A, et al. PALB2 mutations in familial breast and pancreatic cancer. *Fam Cancer*. Jun 2011; 10(2):225-231. PMID 21365267
81. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science*. Apr 10 2009; 324(5924):217. PMID 19264984
82. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. *Clin Genet*. Nov 2010; 78(5):490-494. PMID 20412113
83. Nguyen-Dumont T, Hammet F, Mahmoodi M, et al. Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry. *Breast Cancer Res Treat*. Jan 2015; 149(2):547-554. PMID 25575445

84. Erkko H, Dowty JG, Nikkila J, et al. Penetrance analysis of the PALB2 c.1592delT founder mutation. *Clin Cancer Res*. Jul 15 2008; 14(14):4667-4671. PMID 18628482
85. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. *Breast Cancer Res*. 2007; 9(6):R83. PMID 18053174
86. Cybulski C, Lubinski J, Wokolorczyk D, et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. *Clin Genet*. Oct 2015; 88(4):366-370. PMID 25330149
87. Southey MC, Teo ZL, Dowty JG, et al. A PALB2 mutation associated with high risk of breast cancer. *Breast Cancer Res*. 2010; 12(6):R109. PMID 21182766
88. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. *N Engl J Med*. Aug 7 2014; 371(6):497-506. PMID 25099575
89. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. *Lancet Oncol*. Jun 2015; 16(6):638-644. PMID 25959805
90. Thompson ER, Goringe KL, Rowley SM, et al. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls. *Breast Cancer Res*. 2015; 17(1):111. PMID 26283626
91. Antoniou AC, Foulkes WD, Tischkowitz M, et al. Breast cancer risk in women with PALB2 mutations in different populations. *Lancet Oncol*. Aug 2015; 16(8):e375-376. PMID 26248842
92. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *J Clin Oncol*. Nov 1 2015; 33(31):3660-3667. PMID 26324357
93. Yang Y, Zhang F, Wang Y, et al. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. *Asian Pac J Cancer Prev*. 2012; 13(7):3501-3505. PMID 22994785
94. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol*. Feb 1 2008; 26(4):542-548. PMID 18172190
95. Huzarski T, Cybulski C, Wokolorczyk D, et al. Survival from breast cancer in patients with CHEK2 mutations. *Breast Cancer Res Treat*. Apr 2014; 144(2):397-403. PMID 24557336
96. Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. *Br J Cancer*. Aug 26 2014; 111(5):1004-1013. PMID 24918820
97. Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *J Clin Oncol*. Dec 10 2012; 30(35):4308-4316. PMID 23109706
98. Goldfeder RL, Priest JR, Zook JM, et al. Medical implications of technical accuracy in genome sequencing. *Genome Med*. Mar 02 2016; 8(1):24. PMID 26932475
99. Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. *Genet Med*. Sep 2013; 15(9):733-747. PMID 23887774
100. Mu W, Lu HM, Chen J, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. *J Mol Diagn*. Nov 2016; 18(6):923-932. PMID 27720647
101. Blue Cross Blue Shield Association. Genetic Testing for Inherited BRCA1 or BRCA2 Mutations. *Technol Eval Cent Assess Program Exec Summ*. June 1997; 12(4):1-44.
102. Southey MC, Goldgar DE, Winqvist R, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *J Med Genet*. Dec 2016; 53(12):800-811. PMID 27595995
103. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 2.2016.
https://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf. Accessed September, 2016.

104. National Institute for Health and Care Excellence (NICE). Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer [CG164]. 2013; updated 2015; www.nice.org.uk/guidance/cg164. Accessed May 12, 2016.
105. Schrag D, Kuntz KM, Garber JE, et al. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. *JAMA*. Feb 2 2000; 283(5):617-624. PMID 10665701
106. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. *J Clin Oncol*. Feb 1 2008; 26(4):542-548. PMID 18172190
107. Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. *Genet Epidemiol*. Jul 2016; 40(5):425-431. PMID 27112364
108. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst*. Jun 1 2005; 97(11):813-822. PMID 15928302
109. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet*. Aug 2006; 38(8):873-875. PMID 16832357